

SPONSORSHIP AGREEMENT



Parties to this agreement:

Diabetesforeningen
Stationsparken 24, st. tv
2600 Glostrup
Denmark
CVR No. 35231528

("Recipient")

Novo Nordisk Denmark A/S
Att.: Thomas Degenhardt
Kay Fiskers Plads 10, 7 floor
2300 København S
CVR No. 38180045

("Novo Nordisk")

1. Summary

- 1.1 Recipient's request for support.** The appendix titled "Recipient's request for support" details the specifics of the Recipient's activity(ies) ("the Activity") supported by the sponsorship and purpose of the Activity.

Title of Activity	Diabetesforeningens Årsmøde 2024
The Sponsorship	<p>Novo Nordisk will provide 10,000 DKK (+ VAT) to support the Recipient's request.</p> <p>Novo Nordisk will not make any non-financial transfers of value.</p> <p>In exchange for the sponsorship, the Recipient shall provide to Novo Nordisk the tangible benefit of: booth space, power, breakfast, lunch, two tickets to the event and recognition as a sponsor.</p> <p>Novo Nordisk is the one of several sponsors of the activity.</p>
Agreement Duration	This agreement starts on 25 th of May 2024 and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient's Duties

- 2.1 Compliance with law and ethics.** The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

- 2.2 Carry out the Activity with proper conduct.** The Recipient shall carry out the Activity independently and in compliance with Novo Nordisk standards and industry codes, in Denmark called ENLI (Etisk nævn for lægemiddelindustrien).

No use of funds for entertainment	Do not use the sponsorship for leisure or social activities
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity
Reasonable payment and awards	If sponsorship is used for awards or other payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as 'HCPs') and patients
Reasonable choice of venue	Hold activities in a location suitable for the Activity with modest hospitality
Reasonable travel	If sponsorship is used for Activity-related travel, carry out within reasonable time and cost

- 2.3 Physical items provided as-is.** If Novo Nordisk donates physical items, the Recipient is solely responsible for the use of such items, and shall assure proper handling and storage of sponsored items after delivery. Novo Nordisk is not liable for the Recipient's use of sponsored items and is not required to carry insurance or take any other measures to protect sponsored items after delivery. Novo Nordisk provides such items as-is and without any representation or warranty of quality or performance.
- 2.4 Internal approvals.** The Recipient shall obtain all necessary approvals related to the receipt of the sponsorship.
- 2.5 Inform Novo Nordisk of changes.** The Recipient shall inform Novo Nordisk of any changes affecting the request for support. If Novo Nordisk determines the change affects its compliance requirements, Novo Nordisk may demand full or partial return of sponsorship, at the discretion of Novo Nordisk. In the case of return, the Recipient shall comply within 14 days.
- 2.6 Provide documentation within 1 month.** The Recipient shall provide Novo Nordisk with documentation that the sponsorship was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.
- 2.7 Disclose Novo Nordisk as sponsorship provider.** The Recipient shall mention Novo Nordisk as the provider of the sponsorship in any public communications or advertising related to the Activity.
- 2.8 Do not use Novo Nordisk branding without approval.** The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.
- 2.9 Allow Novo Nordisk to use Recipient's logo.** The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's sponsorship.

3. Requirements for Financial Sponsorships

- 3.1 Payment after receipt of invoice.** Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Sponsorship amount payable
- VAT or other tax amount payable
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient Thomas Degenhardt (TDEG)

- 3.2 Refund unspent amounts.** The Recipient shall refund to Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

4. Other Terms and Conditions

- 4.1 Require Public disclosures.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals ("HCPs"), Healthcare Organizations ("HCOs"), and Patient Organizations. In addition to the payment amount, such disclosure may also include Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.

The Recipient will publish information on the Sponsorship on the Recipient's webpage. The information will include the Sponsorship amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Sponsorship. The information must be publicly available for at least two (2) years.

- 4.2 **No incentive to prescribe or recommend.** The sponsorship made by Novo Nordisk indicates no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk's products or services.
- 4.3 **No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the sponsorship and shall promptly inform Novo Nordisk if such conflict of interest is discovered.
- 4.4 **Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://www.novonordisk.com).
- 4.5 **Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.
- 4.6 **Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.

5. Attachments:

The following attachments are part of this agreement:

Attachment A: Recipient's request for support (application form, letter or email), with detailed program plan, timeline and budget

6. Agreed to and Accepted by:

Date: April 18, 2024

Date: April 18, 2024

On behalf of Recipient:

On behalf of Novo Nordisk:

DocuSigned by:
Søren Biune
7AB25D4ADD43E...

DocuSigned by:
Thomas Degenhardt
8509ET3322094F8...

Name: Søren Biune

Name: Thomas Degenhardt

Title: Forretningschef

Title: Brand Lead

Attachment A: Recipient's Request for Support

1. Copy of the Recipient's sponsorship request



VELKOMMEN!

Hvad byder fremtiden på i forhold til blodsuktermåling? Hvordan kan det at kende dit blodsukker være med til at påvirke din type 2-diabetes? Hvordan går det egentlig med diabetesbehandlingen i Danmark, set fra de regionale Steno-centre? Alt det og meget mere kan du få svar på til **Diabetesforeningens årsmøde**, der i år både byder på diabeteseksperter, paneldebat, brugererfaringer, stande og en musikoplevelse med Danmarks førende gospel- og soul-diva **Marie Carmen Koppel**.

Sidst, men ikke mindst løfter vi sløret for, hvilke tre forskningsprojekter, der blevet er udvalgt af Diabetesforeningens brugerpanel til **årets forskningslegater på hver 600.000 kroner**. Vi glæder os til at samle samarbejdspartnere, fagfolk, politikere, medlemmer og frivillige om #diabeteskampen, til en dag med spændende oplæg og mulighed for at netværke.

Hvor og hvornår

Lørdag d. 25. maj 2024 i ODEON, Odeons Kvarter 1, Odense C

Program

- 09.00-10.00** Registrering, morgenmad og besøg på stande
- 10.00-10.10** Velkomst
Formand Jørgen Andersen, Diabetesforeningen
- 10.10-10.30** Blodsuktermåling nu og i fremtiden
Forskningschef Tanja Thybo, Diabetesforeningen
- 10.30-11.00** Hvilken betydning har kontrolleret måling af blodsukker for mennesker med type 2-diabetes?
Paneldebat med tre medlemmer, der har afprøvet en sensor i to uger. Moderator: Claus Baggild, Diabetesforeningen
- 11.00-11.20** Pause og besøg på stande
- 11.20-11.50** Den bruger- og behovsstyrede behandling af diabetes
Jan Erik Henriksen, Centerdirektør, Steno Diabetes Center Odense
- 11.50-12.20** Uddeling af Diabetesforeningens forskningslegater
- 12.20-12.30** Musikalsk indslag: Marie Carmen Koppel
Marie Carmen Koppel, sangerinde og diabetesambassader i Diabetesforeningen
- 12.00-12.30** Uddeling af Diabetesforeningens forskningslegater
- 12.30-13.30** Frokost
(egenbetaling kr. 275 for ikke-delegerede)
Årsmøde slutter.


Diabetesforeningens delegeretmøde

Har du lyst til at høre mere om Diabetesforeningens vigtige arbejde i 2023 og i de kommende år?


Så bliv hængende til delegeretmøde kl. 13.30-16.45. Her stiller vi skarpt på, hvordan Diabetesforeningen i fremtiden kan tiltrække flere medlemmer med type 2-diabetes, og hvordan vi kan skabe endnu mere plads til endnu flere ildsjæle.

- 13.00-13.30** Besøg på stande og registrering af nyankomne til delegeretmøde
- 13.30-16.45** Diabetesforeningens vedtægtsbestemte delegeretmøde.

Med venlig hilsen


Jørgen Andersen
Formand for Diabetesforeningen




Claus Richter
Adm. direktør i Diabetesforeningen

2. Activity timelines and budget

Sponsorship Agreement, DK, 2022-DEC
Local Adaptation of HQ Sponsorship Agreement v2
July 2021



Thomas Degenhardt
Novo Nordisk

Glostrup 12. marts 2024

**Ordrebekræftelse stand leje inkl. deltagelse af to personer fra
Novo Nordisk ifm. Diabetesforeningens Års- og Delegeretmøde
den 25. maj 2024 på Odeon, Odeons Kvarter 1, 5000 Odense.**

Jeg bekræfter hermed jeres ordre på en 8m2 stand til en pris på 10.000 kr. + moms
Inkl. strøm, hvid dug, morgenmad, frokost, eftermiddagskaffe samt interessante indlæg.

Jeg ser frem til at modtage jeres PO-nummer.

Med venlig hilsen
Diabetesforeningen



Søren Biune